TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23102903

Group type: EXPERIMENTAL
Intervention: Purified antithrombin supplementation to reach an antithrombin activity value of 120%
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no antithrombin supplementation)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Purified antithrombin supplementation
Number of subjects: 200
Study: 19940233

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg plus Rabeprazole 10 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg (once daily)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg (4 times per day)
Number of subjects: 15
Study: 17881004

Group type: EXPERIMENTAL
Intervention: 20% CO(2) challenge
Number of subjects: 404

Group type: COMPARATOR
Intervention: Control for gender and trait anxiety
Number of subjects: 404
Study: 16172491

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine plus erythromycin (SP plus E)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Severely malnourished children
Number of subjects: 0
Study: 12576938

Group type: EXPERIMENTAL
Intervention: Filgrastim (300 microg/day) administered as a 30-min intravenous infusion for 5 days or until white blood cell count reached >75.0 x 10(9) cells/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard antibiotic therapy with filgrastim
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antibiotic therapy with placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 0
Study: 10389953

Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg intravenous (IV) ketorolac
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 8678098

Group type: EXPERIMENTAL
Intervention: Cefepime 2 g every 12 hours
Number of subjects: 882

Group type: COMPARATOR
Intervention: Ceftazidime 2 g every 8 hours
Number of subjects: 882

Group type: EXPERIMENTAL
Intervention: Cefepime and Ceftazidime
Number of subjects: 882
Study: 1878532

Group type: EXPERIMENTAL
Intervention: GMS-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GMS-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GMS formulation (multiple dosing)
Number of subjects: 0
Study: 6849731

Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide (25 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31031180

Group type: EXPERIMENTAL
Intervention: Theory of Planned Behavior (TPB)‐driven message
Number of subjects: 160
Study: 26751602

Group type: EXPERIMENTAL
Intervention: Conically shaped interdental brushes
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cylindrically shaped interdental brushes
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both IDB types
Number of subjects: 51
Study: 25327222

Group type: EXPERIMENTAL
Intervention: Lemongrass mouthrinse
Number of subjects: 20
Study: 23524015

Group type: EXPERIMENTAL
Intervention: extrafine BDP/F 400/24 μg/day pMDI
Number of subjects: 416

Group type: COMPARATOR
Intervention: FP/S 500/100 μg/day Diskus®
Number of subjects: 416
Study: 20975611

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor group
Number of subjects: 20

Group type: COMPARATOR
Intervention: No angiotensin-converting enzyme inhibitor group
Number of subjects: 20
Study: 19118243

Group type: EXPERIMENTAL
Intervention: High-dose B vitamin supplementation (5 mg folic acid + 0.4 mg vitamin B12 + 50 mg vitamin B6)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: High-dose B vitamin supplementation
Number of subjects: 506
Study: 17159081

Group type: EXPERIMENTAL
Intervention: Aliskiren + Hydrochlorothiazide (150 mg + 25 mg)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Aliskiren + Ramipril (75 mg or 150 mg)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Aliskiren + Irbesartan (75 mg or 150 mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Aliskiren (150 mg) alone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Aliskiren + Hydrochlorothiazide
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Aliskiren + Ramipril
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Aliskiren + Irbesartan
Number of subjects: 67
Study: 15120684

Group type: EXPERIMENTAL
Intervention: Oral diazepam prophylaxis
Number of subjects: 110

Group type: COMPARATOR
Intervention: No oral prophylaxis (Control)
Number of subjects: 110
Study: 11100761

Group type: EXPERIMENTAL
Intervention: Low-dose nitroglycerin (3 microg per kg heart weight per min)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bolus nitroglycerin (2 mg into the aortic root)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (ctr)
Number of subjects: 46
Study: 9211441

Group type: EXPERIMENTAL
Intervention: IMI plus LRZ
Number of subjects: 49
Study: 8249556

Group type: EXPERIMENTAL
Intervention: 5 mg nitrendipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 mg nitrendipine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3698063

Group type: EXPERIMENTAL
Intervention: Rociverine (20 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flavoxate (200 mg)
Number of subjects: 40
Study: 30589349

Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification (IBM)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IBM
Number of subjects: 50

Group type: COMPARATOR
Intervention: PMR
Number of subjects: 50
Study: 28378403

Group type: EXPERIMENTAL
Intervention: 3.5 μg haemagglutinin vaccine
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 6 μg haemagglutinin vaccine
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 9 μg haemagglutinin vaccine
Number of subjects: 256

Group type: COMPARATOR
Intervention: 15 μg haemagglutinin vaccine
Number of subjects: 256
Study: 25175385

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 23644819

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid biomarker levels (total tau, phosphorylated tau [181P], amyloid beta 1‐42)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid biomarker levels (phosphorylated tau/total tau, phosphorylated tau/amyloid beta)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Medications (deprenyl and/or tocopherol)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Total tau or total tau/amyloid beta levels
Number of subjects: 403
Study: 21336109

Group type: EXPERIMENTAL
Intervention: Rescue therapy (including prone positioning, inhaled vasodilators, high-frequency ventilation, extracorporeal membrane oxygenation)
Number of subjects: 2632

Group type: COMPARATOR
Intervention: Prone positioning
Number of subjects: 2632
Study: 19521298

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 7.5 mg/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 12.5 mg/h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 17.5 mg/h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study: 17584813

Group type: EXPERIMENTAL
Intervention: Writing intervention (one-month duration)
Number of subjects: 41
Study: 15002318

Group type: EXPERIMENTAL
Intervention: berlition 300 oral
Number of subjects: 56

Group type: COMPARATOR
Intervention: vitamin B1
Number of subjects: 56
Study: 11463549

Group type: EXPERIMENTAL
Intervention: Transmyocardial laser revascularization (TMLR) plus standard medical management
Number of subjects: 188

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 188
Study: 10188753

Group type: EXPERIMENTAL
Intervention: Preexercise carbohydrate (CHO) containing breakfast (100 g CHO) 3 h before exercise
Number of subjects: 7

Group type: COMPARATOR
Intervention: Overnight fast (FASTED)
Number of subjects: 7
Study: 7573564

Group type: EXPERIMENTAL
Intervention: Single bout of maximal cycle ergometry (exercise)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no exercise after HDT)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study: 2186623

Group type: EXPERIMENTAL
Intervention: 0.5% podofilox solution
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 556536

Group type: EXPERIMENTAL
Intervention: Interposition mesocaval shunt
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Interposition splenocaval shunt
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Interposition mesorenal shunt
Number of subjects: 2
Study: 29958027

Group type: EXPERIMENTAL
Intervention: Multimicronutrient syrup
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dietary supplements (nine snack recipes rich in micronutrients)
Number of subjects: 90

Group type: COMPARATOR
Intervention: DM controls
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group 1 (DM controls) vs Group 3 (dietary supplements)
Number of subjects: 90
Study: 28435031

Group type: EXPERIMENTAL
Intervention: Vibrating-mesh-nebulizer (Aerogen Solo; VMN) with humidification
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Vibrating-mesh-nebulizer (Aerogen Solo; VMN) without humidification
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Metered-dose-inhaler with AeroChamber Vent (MDI-AV) with humidification
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Metered-dose-inhaler with AeroChamber Vent (MDI-AV) without humidification
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Oxycare jet-nebulizer (JN) with humidification
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Oxycare jet-nebulizer (JN) without humidification
Number of subjects: 72
Study: 26040200

Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (DAP) 500 mg ml(‐1) + EDTA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (DAP) 1 mg ml(‐1) + EDTA
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (DAP) 500 mg ml(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Double antibiotic paste (DAP) 1 mg ml(‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: EDTA only
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study: 22441962

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (submaximal treadmill walking, 30 min daily, 3 times a week for 6 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Weighted vest exercise (same as aerobic but with a weighted vest of 4-8% of body weight for 6 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Weighted vest exercise
Number of subjects: 36
Study: 21309695

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg every morning or two times per day as glycinate)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg/day)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (15 mg b.i.d.)
Number of subjects: 52
Study: 19111111

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV) for acute respiratory failure (ARF)
Number of subjects: 0
Study: 17098669

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nadolol plus isosorbide-5-mononitrate (ISMN)
Number of subjects: 61
Study: 14531256

Group type: EXPERIMENTAL
Intervention: General anesthesia (sevoflurane, nitrous oxide in oxygen)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spinal anesthesia (0.5% bupivacaine)
Number of subjects: 40
Study: 10727076

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (21g x d(‐1))
Number of subjects: 14
Study: 8704699

Group type: EXPERIMENTAL
Intervention: Bone marrow stored for 2 years or more
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (selected by diagnosis and date of storage)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bone marrow samples cryopreserved for a median of 4.4 years (range 2.0-7.8)
Number of subjects: 36
Study: 1496149

Group type: EXPERIMENTAL
Intervention: Alternating air mattress
Number of subjects: 57

Group type: COMPARATOR
Intervention: Static air mattress
Number of subjects: 57

Group type: COMPARATOR
Intervention: Water mattress overlay
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Semi-Fowler's position
Number of subjects: 57

Group type: COMPARATOR
Intervention: Recumbent position
Number of subjects: 57

Group type: COMPARATOR
Intervention: Pressure sores incidence
Number of subjects: 57
Study: 6648604

Group type: EXPERIMENTAL
Intervention: Care groups intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control villages without care groups
Number of subjects: 0
Study: 3541166

Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 10
Study: 31175696

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide 6% solution under occlusion for one hour daily for 6 weeks
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide 3% solution
Number of subjects: 145

Group type: COMPARATOR
Intervention: Normal saline 0.9% as a placebo
Number of subjects: 145
Study: 29428121

Group type: EXPERIMENTAL
Intervention: Multimodal intervention (psychiatry, psychology, medicine, occupational therapy, neuropsychology, and family therapy)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Traditional intervention (psychiatry and medicine only)
Number of subjects: 302
Study: 27450909

Group type: EXPERIMENTAL
Intervention: Text Message Alcohol Program (TMAP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (general motivational text messages)
Number of subjects: 60
Study: 24901753

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 22049336

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (pain)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 11
Study: 19656577

Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole (n=373)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Placebo (n=368)
Number of subjects: 741
Study: 18712195

Group type: EXPERIMENTAL
Intervention: Multiskill club (n = 19 children)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (n = 15 children)
Number of subjects: 34
Study: 16433205

Group type: EXPERIMENTAL
Intervention: Celecoxib (CE) 200 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 12732998

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 microg/hr for 7 days postoperatively)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (normal saline for 7 days postoperatively)
Number of subjects: 54
Study: 10666660

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Class III agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azimilide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dronedarone, tedisamal, trecetilide
Number of subjects: 0
Study: 9016418

Group type: EXPERIMENTAL
Intervention: Warfarin recommended for patients with nonrheumatic atrial fibrillation
Number of subjects: 189

Group type: COMPARATOR
Intervention: Warfarin for 85-year-old patients
Number of subjects: 189

Group type: COMPARATOR
Intervention: Warfarin for patients with bleeding risk factors
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Warfarin for patients with a recent stroke
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Warfarin prescription by physicians with good experience
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Warfarin prescription by physicians with favorable opinions
Number of subjects: 189

Group type: COMPARATOR
Intervention: Warfarin prescription despite good experience and favorable opinions
Number of subjects: 189
Study: 1611986

Group type: EXPERIMENTAL
Intervention: Midazolam (Dormicum 7.5 mg)
Number of subjects: 0
Study: 6580807

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 1884

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1884
Study: 30904663

Group type: EXPERIMENTAL
Intervention: fMRI-noise setting
Number of subjects: 50

Group type: COMPARATOR
Intervention: silent setting
Number of subjects: 50
Study: 29574439

Group type: EXPERIMENTAL
Intervention: Early supervised structured exercise programme delivered by physiotherapists, incorporating shoulder-specific exercises, general physical activity, and behavioural strategies.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Best practice usual care only (control group).
Number of subjects: 350
Study: 27169493

Group type: EXPERIMENTAL
Intervention: Nocturnal O2 therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PETCO2
Number of subjects: 12
Study: 24450992

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP; n = 101)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Diabetes self‐care software on a personal digital assistant (PDA; n = 81)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Combination of CDSMP + PDA (n = 99)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Usual care (control; n = 95)
Number of subjects: 376
Study: 22834932

Group type: EXPERIMENTAL
Intervention: Laser + SRP (photoablative intra/extra-pocket de-epithelization with diode laser (λ = 810 nm) and multiple photodynamic treatments (mean ± SD: 3.7 ± 2.4 applications) using diode laser (λ = 635 nm) and 0.3% methylene blue as photosensitizer)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham-laser treatment + SRP
Number of subjects: 26
Study: 20140794

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1305
Study: 18681820

Group type: EXPERIMENTAL
Intervention: Sertraline (up to 50 or 100 mg/day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 15942765

Group type: EXPERIMENTAL
Intervention: Circuit Training (CT)
Number of subjects: 8
Study: 12840633

Group type: EXPERIMENTAL
Intervention: Two bouts of exercise (AM-EX and PM-EX)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PM exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CN)
Number of subjects: 10
Study: 11006058

Group type: EXPERIMENTAL
Intervention: Oral contraceptive and estrogen replacement therapy users
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Men
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Postmenopausal women
Number of subjects: 1027
Study: 9148197

Group type: EXPERIMENTAL
Intervention: Directing attention to the left ear (DL) during the CVT test
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Directing attention to the right ear (DR) during the CVT test
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Directing attention to the left ear (DL) during the FDWT test
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Directing attention to the right ear (DR) during the FDWT test
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fused dichotic words test (FDWT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: CV syllables dichotic listening test (CVT)
Number of subjects: 16
Study: 1507038

Group type: EXPERIMENTAL
Intervention: Experimental group (new electric toothbrush)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control hand group (manual toothbrush)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control electric group (electric toothbrush)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: All three groups (experimental, control hand, control electric)
Number of subjects: 96
Study: 6322565

Group type: EXPERIMENTAL
Intervention: MK 421
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 48
Study: 30723840

Group type: EXPERIMENTAL
Intervention: EAMD + Cal (increased caloric intake)
Number of subjects: 118

Group type: COMPARATOR
Intervention: EAMD Control
Number of subjects: 118

Group type: COMPARATOR
Intervention: OV Control
Number of subjects: 118
Study: 29198064

Group type: EXPERIMENTAL
Intervention: Lyophilisate (120-μg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tablet (200-μg)
Number of subjects: 18
Study: 27981529

Group type: EXPERIMENTAL
Intervention: 100 mg/d regular oral intake of aspirin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 24733781

Group type: EXPERIMENTAL
Intervention: Aromatherapy M technique hand massage
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: M technique without aromatherapy
Number of subjects: 117

Group type: COMPARATOR
Intervention: Nurse presence
Number of subjects: 117
Study: 22227725

Group type: EXPERIMENTAL
Intervention: Fat emulsion with part of the lipid replaced by fish oil (Group B, n = 18)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Mixture of soybean and medium-chain triglyceride oils (Group A, n = 12)
Number of subjects: 38
Study: 20195825

Group type: EXPERIMENTAL
Intervention: Puerarin
Number of subjects: 18
Study: 18547179

Group type: EXPERIMENTAL
Intervention: Dermicol‐P35
Number of subjects: 149

Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) filler Restylane
Number of subjects: 149
Study: 15740537

Group type: EXPERIMENTAL
Intervention: Treatment duration of 48 weeks for cirrhotic patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment duration of 48 weeks for noncirrhotic genotype 1 or 4 patients with elevated alanine aminotransferase levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment duration of 24 weeks for noncirrhotic patients with genotype 2 or 3
Number of subjects: 0
Study: 11788628

Group type: EXPERIMENTAL
Intervention: GH + LHRH analog (LHRH‐A)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: GH alone
Number of subjects: 17